Biogen Inc. (BIIB) beat market expectations on revenue and earnings for the third quarter of 2018. Total revenues grew 12% to $3.4 billion from the prior-year period, helped by strength in SPINRAZA and biosimilars, as well as OCREVUS royalties. On a GAAP basis, net income grew 18% to $1.44 billion and EPS grew 24% to … Continue reading Biogen posts solid Q3 results, topping expectations